Phathom Pharmaceuticals (PHAT) Competitors $4.22 -0.55 (-11.53%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PHAT vs. IRON, TVTX, SDGR, IDYA, MESO, IMCR, INDV, CGON, VERA, and SPRYShould you be buying Phathom Pharmaceuticals stock or one of its competitors? The main competitors of Phathom Pharmaceuticals include Disc Medicine (IRON), Travere Therapeutics (TVTX), Schrödinger (SDGR), IDEAYA Biosciences (IDYA), Mesoblast (MESO), Immunocore (IMCR), Indivior (INDV), CG Oncology (CGON), Vera Therapeutics (VERA), and ARS Pharmaceuticals (SPRY). These companies are all part of the "pharmaceutical products" industry. Phathom Pharmaceuticals vs. Disc Medicine Travere Therapeutics Schrödinger IDEAYA Biosciences Mesoblast Immunocore Indivior CG Oncology Vera Therapeutics ARS Pharmaceuticals Disc Medicine (NASDAQ:IRON) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, community ranking, media sentiment, valuation, risk, analyst recommendations and institutional ownership. Does the media prefer IRON or PHAT? In the previous week, Disc Medicine had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 6 mentions for Disc Medicine and 4 mentions for Phathom Pharmaceuticals. Phathom Pharmaceuticals' average media sentiment score of 1.11 beat Disc Medicine's score of 0.76 indicating that Phathom Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Disc Medicine 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Phathom Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community believe in IRON or PHAT? Phathom Pharmaceuticals received 39 more outperform votes than Disc Medicine when rated by MarketBeat users. However, 86.57% of users gave Disc Medicine an outperform vote while only 72.93% of users gave Phathom Pharmaceuticals an outperform vote. CompanyUnderperformOutperformDisc MedicineOutperform Votes5886.57% Underperform Votes913.43%Phathom PharmaceuticalsOutperform Votes9772.93% Underperform Votes3627.07% Which has higher valuation and earnings, IRON or PHAT? Disc Medicine has higher earnings, but lower revenue than Phathom Pharmaceuticals. Disc Medicine is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$76.43M-$3.99-10.28Phathom Pharmaceuticals$55.25M5.32-$201.59M-$5.35-0.79 Which has more risk & volatility, IRON or PHAT? Disc Medicine has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.35, suggesting that its stock price is 65% less volatile than the S&P 500. Do insiders & institutionals believe in IRON or PHAT? 83.7% of Disc Medicine shares are owned by institutional investors. Comparatively, 99.0% of Phathom Pharmaceuticals shares are owned by institutional investors. 4.2% of Disc Medicine shares are owned by insiders. Comparatively, 24.1% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is IRON or PHAT more profitable? Disc Medicine has a net margin of 0.00% compared to Phathom Pharmaceuticals' net margin of -1,292.14%. Phathom Pharmaceuticals' return on equity of 0.00% beat Disc Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -25.24% -23.96% Phathom Pharmaceuticals -1,292.14%N/A -79.57% Do analysts recommend IRON or PHAT? Disc Medicine currently has a consensus price target of $93.80, indicating a potential upside of 128.78%. Phathom Pharmaceuticals has a consensus price target of $22.17, indicating a potential upside of 425.28%. Given Phathom Pharmaceuticals' higher probable upside, analysts clearly believe Phathom Pharmaceuticals is more favorable than Disc Medicine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09Phathom Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryDisc Medicine beats Phathom Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Remove Ads Get Phathom Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PHAT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PHAT vs. The Competition Export to ExcelMetricPhathom PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$293.87M$6.26B$5.29B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.746.6921.6517.68Price / Sales5.32222.70371.0992.89Price / CashN/A65.6738.1534.64Price / Book-3.325.776.373.94Net Income-$201.59M$142.01M$3.20B$247.45M7 Day Performance-4.74%2.88%1.79%0.48%1 Month Performance-4.31%-13.93%-9.41%-7.08%1 Year Performance-57.93%-12.36%9.61%-0.35% Phathom Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PHATPhathom Pharmaceuticals3.7568 of 5 stars$4.22-11.5%$22.17+425.3%-52.4%$293.87M$55.25M-0.74110Positive NewsIRONDisc Medicine2.5692 of 5 stars$39.20-4.9%$93.80+139.3%+35.4%$1.36BN/A-9.8530High Trading VolumeTVTXTravere Therapeutics2.567 of 5 stars$15.17+1.2%$31.46+107.4%+135.9%$1.35B$233.18M-3.70460Analyst ForecastSDGRSchrödinger2.3417 of 5 stars$18.21+1.0%$32.29+77.3%+0.2%$1.33B$207.54M-7.78790Analyst ForecastInsider TradeNews CoverageIDYAIDEAYA Biosciences3.4351 of 5 stars$15.14+2.9%$53.58+253.9%-59.1%$1.33B$7M-4.5980High Trading VolumeMESOMesoblast2.602 of 5 stars$10.40-1.6%$18.00+73.1%+108.3%$1.32B$5.67M0.0080Gap DownIMCRImmunocore2.1976 of 5 stars$26.28-3.6%$65.18+148.0%-50.8%$1.31B$310.20M-27.66320Analyst ForecastNews CoverageHigh Trading VolumeINDVIndivior3.7687 of 5 stars$9.39+2.6%$15.00+59.7%-53.9%$1.29B$1.19B-26.831,164Short Interest ↓Positive NewsCGONCG Oncology1.1274 of 5 stars$16.92-1.6%$63.88+277.5%-46.6%$1.29B$1.14M-11.9261Analyst ForecastPositive NewsGap UpHigh Trading VolumeVERAVera Therapeutics2.8814 of 5 stars$19.94-6.4%$64.67+224.3%-53.6%$1.27BN/A-7.6440Positive NewsHigh Trading VolumeSPRYARS Pharmaceuticals3.082 of 5 stars$12.83+0.2%$31.00+141.6%+62.2%$1.26B$89.15M-25.1690Positive NewsHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Disc Medicine Alternatives Travere Therapeutics Alternatives Schrödinger Alternatives IDEAYA Biosciences Alternatives Mesoblast Alternatives Immunocore Alternatives Indivior Alternatives CG Oncology Alternatives Vera Therapeutics Alternatives ARS Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PHAT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phathom Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phathom Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PHAT Stock Free PHAT Stock Alerts